Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Lasagna Reeves, Cristian A ^a   Castillo Carranza, Diana L ^a   Sengupta, Urmi ^a   Clos, Audra L ^a   Jackson, George R ^a   Kayed, Rakez ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; MULTIENZYME COMPLEX; OLIGOMER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SEPTIN; SYNAPTOPHYSIN; TAU PROTEIN; UBIQUINONE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; STEREOTAXIC SURGERY;

MUS; MUS MUSCULUS;

EID: 79957913270     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-39     Document Type: Article

References (83)

1. The distribution of tau in the mammalian central nervous system. LI Binder A Frankfurter LI Rebhun, J Cell Biol 1985 10 (Pubitemid 16203754)
2. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. DN Drechsel AA Hyman MH Cobb MW Kirschner, Mol Biol Cell 1992 3 1141 1154 1421571 (Pubitemid 23088964)
3. Neurodegenerative tauopathies. VM Lee M Goedert JQ Trojanowski, Annu Rev Neurosci 2001 24 1121 1159 10.1146/annurev.neuro.24.1.1121 11520930 (Pubitemid 32695256)
4. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. AC Alonso B Li I Grundke-Iqbal K Iqbal, Curr Alzheimer Res 2008 5 375 384 10.2174/156720508785132307 18690834
5. Mechanisms of tau-induced neurodegeneration. K Iqbal F Liu CX Gong AD Alonso I Grundke-Iqbal, Acta Neuropathol 2009 118 53 69 10.1007/s00401-009-0486- 3 19184068
6. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. C Ballatore VM Lee JQ Trojanowski, Nat Rev Neurosci 2007 8 663 672 17684513 (Pubitemid 47283144)
7. Tau protein abnormalities associated with the progression of alzheimer disease type dementia. V Haroutunian P Davies C Vianna JD Buxbaum DP Purohit, Neurobiol Aging 2007 28 1 7 10.1016/j.neurobiolaging.2005.11.001 16343696 (Pubitemid 44791636)
8. Neuropathological stageing of Alzheimer-related changes. H Braak E Braak, Acta Neuropathol 1991 82 239 259 10.1007/BF00308809 1759558
9. Tau pathology: a marker of neurodegenerative disorders. A Delacourte L Buee, Curr Opin Neurol 2000 13 371 376 10.1097/00019052-200008000-00002 10970052
10. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. H Braak I Alafuzoff T Arzberger H Kretzschmar K Del Tredici, Acta Neuropathol 2006 112 389 404 10.1007/s00401-006-0127-z 16906426 (Pubitemid 44469160)
11. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. KR Brunden JQ Trojanowski VM Lee, J Alzheimers Dis 2008 14 393 399 18688089
12. Alzheimer's disease. A new take on tau. J Marx, Science 2007 316 1416 1417 10.1126/science.316.5830.1416 17556561 (Pubitemid 46906589)
13. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. C Andorfer CM Acker Y Kress PR Hof K Duff P Davies, J Neurosci 2005 25 5446 5454 10.1523/JNEUROSCI.4637-04.2005 15930395 (Pubitemid 40770926)
14. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. M Polydoro CM Acker K Duff PE Castillo P Davies, J Neurosci 2009 29 10741 10749 10.1523/JNEUROSCI.1065-09.2009 19710325
15. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Y Yoshiyama M Higuchi B Zhang SM Huang N Iwata TC Saido J Maeda T Suhara JQ Trojanowski VM Lee, Neuron 2007 53 337 351 10.1016/j.neuron.2007.01.010 17270732 (Pubitemid 46161268)
16. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. Z Berger H Roder A Hanna A Carlson V Rangachari M Yue Z Wszolek K Ashe J Knight D Dickson C Andorfer TL Rosenberry J Lewis M Hutton C Janus, J Neurosci 2007 27 3650 3662 10.1523/JNEUROSCI.0587-07.2007 17409229 (Pubitemid 46557687)
17. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. TL Spires JD Orne K SantaCruz R Pitstick GA Carlson KH Ashe BT Hyman, Am J Pathol 2006 168 1598 1607 10.2353/ajpath.2006.050840 16651626
18. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. T Gomez-Isla R Hollister H West S Mui JH Growdon RC Petersen JE Parisi BT Hyman, Ann Neurol 1997 41 17 24 10.1002/ana.410410106 9005861 (Pubitemid 27057088)
19. Do neuronal inclusions kill the cell? RD Terry, J Neural Transm Suppl 2000 59 91 93 10961422 (Pubitemid 30479410)
20. Granular tau oligomers as intermediates of tau filaments. S Maeda N Sahara Y Saito M Murayama Y Yoshiike H Kim T Miyasaka S Murayama A Ikai A Takashima, Biochemistry 2007 46 3856 3861 10.1021/bi061359o 17338548 (Pubitemid 46493485)
21. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. S Maeda N Sahara Y Saito S Murayama A Ikai A Takashima, Neurosci Res 2006 54 197 201 10.1016/j.neures.2005.11.009 16406150 (Pubitemid 43276078)
22. Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam. M Yamazaki M Hasegawa O Mori S Murayama K Tsuchiya K Ikeda KM Chen Y Katayama K Oyanagi, J Neuropathol Exp Neurol 2005 64 839 846 10.1097/01.jnen.0000182977. 79483.89 16215455 (Pubitemid 41434666)
23. Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease. K Neumann G Farias A Slachevsky P Perez RB Maccioni, J Alzheimers Dis
24. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. EE Congdon S Kim J Bonchak T Songrug A Matzavinos J Kuret, J Biol Chem 2008 283 13806 13816 10.1074/jbc.M800247200 18359772
25. Characterization of tau fibrillization in vitro. S Xu KR Brunden JQ Trojanowski VM Lee, Alzheimers Dement 2010 6 110 117 10.1016/j.jalz.2009.06.002 20298971
26. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. SM Huang A Mouri H Kokubo R Nakajima T Suemoto M Higuchi M Staufenbiel Y Noda H Yamaguchi T Nabeshima TC Saido N Iwata, J Biol Chem 2006 281 17941 17951 10.1074/jbc.M601372200 16636059 (Pubitemid 44035593)
27. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. A Mouri Y Noda H Hara H Mizoguchi T Tabira T Nabeshima, FASEB J 2007 21 2135 2148 10.1096/fj.06-7685com 17341681 (Pubitemid 47026449)
28. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. H Scholtzova YZ Wadghiri M Douadi EM Sigurdsson YS Li D Quartermain P Banerjee T Wisniewski, J Neurosci Res 2008 86 2784 2791 10.1002/jnr.21713 18615702
29. Learning-memory deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by using tetrahydroxystilbene glucoside. L Zhang Y Xing CF Ye HX Ai HF Wei L Li, Behav Brain Res 2006 173 246 254 10.1016/j.bbr.2006. 06.034 16901557 (Pubitemid 44291828)
30. Template-assisted filament growth by parallel stacking of tau. M Margittai R Langen, Proc Natl Acad Sci USA 2004 101 10278 10283 10.1073/pnas.0401911101 15240881 (Pubitemid 38924916)
31. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. M Perez JM Valpuesta M Medina E Montejo de Garcini J Avila, J Neurochem 1996 67 1183 1190 8752125 (Pubitemid 26277931)
32. Neurofibrillary tangles in the dementia of "normal pressure" hydrocephalus. MJ Ball, Can J Neurol Sci 1976 3 227 235 1000408 (Pubitemid 8067173)
33. Neurofibrillary degeneration and neuronal loss in Alzheimer's disease. W Bondareff CQ Mountjoy M Roth DL Hauser, Neurobiol Aging 1989 10 709 715 10.1016/0197-4580(89)90007-9 2628782 (Pubitemid 20059504)
34. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. MJ West PD Coleman DG Flood JC Troncoso, Lancet 1994 344 769 772 10.1016/S0140-6736(94)92338-8 7916070 (Pubitemid 24283954)
35. The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. MJ West CH Kawas LJ Martin JC Troncoso, Ann N Y Acad Sci 2000 908 255 259 10911964 (Pubitemid 30462009)
36. Preparation and characterization of neurotoxic tau oligomers. CA Lasagna-Reeves DL Castillo-Carranza MJ Guerrero-Muoz GR Jackson R Kayed, Biochemistry 2010 49 10039 10041 10.1021/bi1016233 21047142
37. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. JD Greene AD Baddeley JR Hodges, Neuropsychologia 1996 34 537 551 10.1016/0028-3932(95)00151-4 8736567 (Pubitemid 26154491)
38. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. LC Schmued KJ Hopkins, Brain Res 2000 874 123 130 10.1016/S0006-8993(00)02513-0 10960596
39. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. LC Schmued KJ Hopkins, Toxicol Pathol 2000 28 91 99 10.1177/019262330002800111 10668994 (Pubitemid 30078209)
40. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. RD Terry E Masliah DP Salmon N Butters R DeTeresa R Hill LA Hansen R Katzman, Ann Neurol 1991 30 572 580 10.1002/ana.410300410 1789684
41. Synaptic slaughter in Alzheimer's disease. PD Coleman PJ Yao, Neurobiol Aging 2003 24 1023 1027 10.1016/j.neurobiolaging.2003.09.001 14643374 (Pubitemid 37487880)
42. Different presynaptic roles of synapsins at excitatory and inhibitory synapses. D Gitler Y Takagishi J Feng Y Ren RM Rodriguiz WC Wetsel P Greengard GJ Augustine, J Neurosci 2004 24 11368 11380 10.1523/JNEUROSCI.3795-04.2004 15601943 (Pubitemid 39658272)
43. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. EM Mutisya AC Bowling MF Beal, J Neurochem 1994 63 2179 2184 7964738 (Pubitemid 24369993)
44. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. H Schagger TG Ohm, Eur J Biochem 1995 227 916 921 10.1111/j.1432-1033.1995.tb20219.x 7867655
45. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. SH Kim R Vlkolinsky N Cairns M Fountoulakis G Lubec, Life Sci 2001 68 2741 2750 10.1016/S0024-3205(01)01074-8 11400916 (Pubitemid 32455678)
46. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. DC David S Hauptmann I Scherping K Schuessel U Keil P Rizzu R Ravid S Drose U Brandt WE Muller A Eckert J Götz, J Biol Chem 2005 280 23802 23814 10.1074/jbc.M500356200 15831501 (Pubitemid 40884866)
47. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. RA Quintanilla TA Matthews-Roberson PJ Dolan GV Johnson, J Biol Chem 2009 284 18754 18766 10.1074/jbc.M808908200 19389700
48. Mitochondrial function in brain tissue in primary degenerative dementia. NR Sims JM Finegan JP Blass DM Bowen D Neary, Brain Res 1987 436 30 38 10.1016/0006-8993(87)91553-8 3690351 (Pubitemid 17167132)
49. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. MY Aksenov HM Tucker P Nair MV Aksenova DA Butterfield S Estus WR Markesbery, Neurochem Res 1999 24 767 774 10.1023/A:1020783614031 10447460 (Pubitemid 29270460)
50. Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. M Mercken M Vandermeeren U Lubke J Six J Boons E Vanmechelen A Van de Voorde J Gheuens, J Neurochem 1992 58 548 553 10.1111/j.1471-4159.1992.tb09754.x 1729400
51. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. Q Li A Lau TJ Morris L Guo CB Fordyce EF Stanley, J Neurosci 2004 24 4070 4081 10.1523/JNEUROSCI.0346-04.2004 15102922 (Pubitemid 38544233)
52. Apoptosis control by death and decoy receptors. A Ashkenazi VM Dixit, Curr Opin Cell Biol 1999 11 255 260 10.1016/S0955-0674(99)80034-9 10209153 (Pubitemid 29164042)
53. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. TT Rohn RA Rissman MC Davis YE Kim CW Cotman E Head, Neurobiol Dis 2002 11 341 354 10.1006/nbdi.2002.0549 12505426 (Pubitemid 36135697)
54. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. C Haass DJ Selkoe, Nat Rev Mol Cell Biol 2007 8 101 112 10.1038/nrm2101 17245412 (Pubitemid 46432529)
55. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. CG Glabe, Neurobiol Aging 2006 27 570 575 10.1016/j.neurobiolaging. 2005.04.017 16481071 (Pubitemid 43290525)
56. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. B Caughey GS Baron B Chesebro M Jeffrey, Annu Rev Biochem 2009 78 177 204 10.1146/annurev.biochem.78.082907.145410 19231987
57. Tau suppression in a neurodegenerative mouse model improves memory function. K Santacruz J Lewis T Spires J Paulson L Kotilinek M Ingelsson A Guimaraes M DeTure M Ramsden E McGowan C Forster M Yue J Orne C Janus A Mariash M Kuskowski B Hyman M Hutton KH Ashe, Science 2005 309 476 481 10.1126/science.1113694 16020737 (Pubitemid 40994688)
58. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. MM Mocanu A Nissen K Eckermann I Khlistunova J Biernat D Drexler O Petrova K Schonig H Bujard E Mandelkow L Zhou G Rune EM Mandelkow, J Neurosci 2008 28 737 748 10.1523/JNEUROSCI.2824-07.2008 18199773 (Pubitemid 351159036)
59. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. R Kayed GR Jackson, Curr Opin Immunol 2009 21 359 363 10.1016/j.coi.2009.05.001 19482462
60. Impaired recognition memory in patients with lesions limited to the hippocampal formation. JM Reed LR Squire, Behav Neurosci 1997 111 667 675 9267644 (Pubitemid 27335378)
61. Impaired recognition memory in monkeys after damage limited to the hippocampal region. SM Zola LR Squire E Teng L Stefanacci EA Buffalo RE Clark, J Neurosci 2000 20 451 463 10627621 (Pubitemid 30220531)
62. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. JJ Kril S Patel AJ Harding GM Halliday, Acta Neuropathol 2002 103 370 376 10.1007/s00401-001-0477-5 11904757 (Pubitemid 36097032)
63. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. H Braak E Braak, Brain Pathol 1991 1 213 216 10.1111/j.1750-3639.1991.tb00661.x 1669710
64. Tau aggregation in the hippocampal formation: an ageing or a pathological process? A Delacourte N Sergeant A Wattez CA Maurage F Lebert F Pasquier JP David, Exp Gerontol 2002 37 1291 1296 10.1016/S0531-5565(02)00141-9 12470843 (Pubitemid 35418288)
65. Prion-like transmission of protein aggregates in neurodegenerative diseases. P Brundin R Melki R Kopito, Nat Rev Mol Cell Biol 2010 11 301 307 10.1038/nrm2873 20308987
66. Transmission and spreading of tauopathy in transgenic mouse brain. F Clavaguera T Bolmont RA Crowther D Abramowski S Frank A Probst G Fraser AK Stalder M Beibel M Staufenbiel M Jucker M Goedert M Tolnay, Nat Cell Biol 2009 11 909 913 10.1038/ncb1901 19503072
67. Prion-like mechanisms in neurodegenerative diseases. B Frost MI Diamond, Nat Rev Neurosci 2010 11 155 159 20029438
68. Extracellular tau is toxic to neuronal cells. A Gomez-Ramos M Diaz-Hernandez R Cuadros F Hernandez J Avila, FEBS Lett 2006 580 4842 4850 10.1016/j.febslet.2006.07.078 16914144 (Pubitemid 44286844)
69. Propagation of tau misfolding from the outside to the inside of a cell. B Frost RL Jacks MI Diamond, J Biol Chem 2009 284 12845 12852 10.1074/jbc.M808759200 19282288
70. Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. M Diaz-Hernandez A Gomez-Ramos A Rubio R Gomez-Villafuertes JR Naranjo MT Miras-Portugal J Avila, J Biol Chem 2010 285 32539 32548 10.1074/jbc.M110.145003 20634292
71. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. GP Davey S Peuchen JB Clark, J Biol Chem 1998 273 12753 12757 10.1074/jbc.273.21.12753 9582300 (Pubitemid 28246828)
72. Threshold effects and control of oxidative phosphorylation in nonsynaptic rat brain mitochondria. GP Davey JB Clark, J Neurochem 1996 66 1617 1624 8627318 (Pubitemid 26090563)
73. Cortical synapse loss in progressive supranuclear palsy. EH Bigio MB Vono S Satumtira J Adamson E Sontag LS Hynan CL White M Baker M Hutton, J Neuropathol Exp Neurol 2001 60 403 410 11379815 (Pubitemid 32467097)
74. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. JL Price AI Ko MJ Wade SK Tsou DW McKeel JC Morris, Arch Neurol 2001 58 1395 1402 10.1001/archneur.58.9.1395 11559310 (Pubitemid 32845990)
75. Cholinergic vesicular transporters in progressive supranuclear palsy. M Suzuki TJ Desmond RL Albin KA Frey, Neurology 2002 58 1013 1018 11940684 (Pubitemid 34298538)
76. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. E Thies EM Mandelkow, J Neurosci 2007 27 2896 2907 10.1523/JNEUROSCI.4674-06.2007 17360912 (Pubitemid 46438993)
77. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. T Kimura T Fukuda N Sahara S Yamashita M Murayama T Mizoroki Y Yoshiike B Lee I Sotiropoulos S Maeda A Takashima, J Biol Chem 2010 285 38692 38699 10.1074/jbc.M110.136630 20921222
78. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. DC Lu S Rabizadeh S Chandra RF Shayya LM Ellerby X Ye GS Salvesen EH Koo DE Bredesen, Nat Med 2000 6 397 404 10.1038/74656 10742146 (Pubitemid 30208156)
79. Caspase-9. K Kuida, Int J Biochem Cell Biol 2000 32 121 124 10.1016/S1357-2725(99)00024-2 10687948 (Pubitemid 30001816)
80. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. M Hashimoto E Rockenstein L Crews E Masliah, Neuromolecular Med 2003 4 21 36 10.1385/NMM:4:1-2:21 14528050
81. In vitro and in vivo neurotoxicity of prion protein oligomers. S Simoneau H Rezaei N Sales G Kaiser-Schulz M Lefebvre-Roque C Vidal JG Fournier J Comte F Wopfner J Grosclaude H Schätzl CI Lasmézas, PLoS Pathog 2007 3 125 10.1371/journal.ppat.0030125 17784787
82. Caspase activation precedes and leads to tangles. A de Calignon LM Fox R Pitstick GA Carlson BJ Bacskai TL Spires-Jones BT Hyman, Nature 464 1201 1204
83. Side chain-dependent stacking modulates tau filament structure. M Margittai R Langen, J Biol Chem 2006 281 37820 37827 10.1074/jbc.M605336200 17023423 (Pubitemid 46042084)